Recent performance snapshot

ProAssurance (PRA) has attracted fresh attention after recent trading left the stock at a last close of US$24.42, with returns mixed across shorter timeframes and longer horizons.

Over the past day, the stock gained 1.83%, while it was roughly flat over the past week and down about 1% over the past month and past 3 months. Year to date, ProAssurance shows a total return of 1.67%, and over the past year about 5.53%, with a very large total return over 3 years and a 2.33% total return over 5 years.

Recent share price moves have been muted, with a 1-day share price return of 1.83% set against a modest 1.67% year-to-date gain, while the 3-year total shareholder return of 76.19% reflects a much stronger longer term outcome.

If you are weighing ProAssurance against other opportunities in the market, this can be a good moment to broaden your search and check out the 20 top founder-led companies

With ProAssurance trading just below its US$25 analyst price target, recent returns stable rather than explosive, and annual revenue edging lower while net income rises, is the stock quietly undervalued, or is the market already pricing in its next phase of growth?

Price-to-Earnings of 19.3x: Is it justified?

On a P/E basis, ProAssurance looks expensive, with its 19.3x multiple sitting above both peers and the broader US insurance industry, even as the last close sits at $24.42.

The P/E ratio compares the current share price with earnings per share, so a higher multiple usually means investors are willing to pay more today for each dollar of profit. For an insurance stock like ProAssurance, that often reflects expectations around earnings quality, growth in underwriting profits, or improved profitability from existing books of business.

Here, earnings have a few supportive data points. ProAssurance became profitable over the past 5 years with earnings growing 9.3% per year, and earnings grew 54.1% over the past year. Current net profit margins are 6%, higher than 3.7% a year earlier, and earnings are forecast to grow 8.56% per year, even though revenue is expected to decline 2.8% per year. This mix suggests the market may be assigning a premium multiple to what is seen as improving profitability and high quality earnings, rather than to top line expansion.

Compared with both a peer average P/E of 16.4x and the US insurance industry average of 10.6x, ProAssurance is priced at a clear premium. It also trades well above an estimated fair P/E of 9.8x, a level the market could move toward if expectations around earnings durability or growth cool from current assumptions.

Result: Price-to-Earnings of 19.3x (OVERVALUED)

However, the higher P/E and annual revenue decline of 2.82% leave little room for disappointment if profitability momentum slows or if underwriting conditions become less favorable.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of optimism and caution leaves you unsure, that is a useful signal to check the underlying data yourself and act promptly. To understand exactly what the market seems to favor at the moment, take a closer look at the 2 key rewards

Looking for more investment ideas?

ProAssurance may have your attention right now, but some of the most compelling opportunities often sit just outside your current watchlist, so do not miss them.

• Spot opportunities that look mispriced by the market and compare their potential using the 47 high quality undervalued stocks.
• Strengthen your portfolio's foundations by hunting for companies with robust finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Get ahead of the crowd by scanning the screener containing 22 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.